Decibel Therapeutics (Nasdaq:DBTX) - Aandelenkoers, Nieuws & Analyse

DBTX Overzicht aandelen

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Meer informatie

DBTX fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

De winst is de afgelopen 5 jaar met 20.1% per jaar gedaald

Decibel Therapeutics, Inc. Concurrenten

Seres Therapeutics

NasdaqGS:MCRB

US$131.2m

Pyxis Oncology

NasdaqGS:PYXS

US$113.0m

Kinnate Biopharma

NasdaqGS:KNTE

US$125.1m

Cidara Therapeutics

NasdaqCM:CDTX

US$143.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Decibel Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$4.91
52 Week Hoogtepunt	US$5.40
52 Week Laag	US$1.61
Bèta	-0.40
11 maand verandering	-3.91%
3 maanden verandering	40.29%
1 Jaar Verandering	65.88%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-72.77%

Recent nieuws en updates

Recent updates

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Aug 10

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

Feb 07

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Oct 17

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Sep 01

Decibel Therapeutics: Gene Therapies For Hearing Loss

Jul 06

Rendement voor aandeelhouders

	DBTX	US Biotechs	US Markt
7D	0%	2.5%	2.2%
1Y	65.9%	16.1%	31.6%

Rendement versus industrie: DBTX overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 16.1 % opleverde.

Rendement versus markt: DBTX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.6 %.

Prijsvolatiliteit

Is DBTX's price volatile compared to industry and market?
DBTX volatility
DBTX Average Weekly Movement	25.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van DBTX is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van DBTX is het afgelopen jaar gestegen van 17% naar 25%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	68	Laurence Reid	www.decibeltx.com

Decibel Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Decibel Therapeutics zich tot de beurswaarde?
DBTX fundamentele statistieken
Marktkapitalisatie	US$124.35m
Inkomsten(TTM)	-US$63.39m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-2.0x

Koers/Winstverhouding

Is DBTX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DBTX resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$63.39m
Inkomsten	-US$63.39m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.50
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde DBTX op de lange termijn?

Bekijk historische prestaties en vergelijking

DBTX Overzicht aandelen

Risicoanalyse

Decibel Therapeutics, Inc. Concurrenten

NasdaqGS:MCRB

US$131.2m

NasdaqGS:PYXS

US$113.0m

NasdaqGS:KNTE

US$125.1m

NasdaqCM:CDTX

US$143.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Decibel Therapeutics, Inc. Files Form 15

New major risk - Revenue and earnings growth

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index

Decibel Therapeutics, Inc. Announces Board Changes

Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) entered into a definitive agreement to acquire remaining unknown majority stake in Decibel Therapeutics, Inc. (NasdaqGS:DBTX) from a group of shareholders for approximately $100 million.

Recent updates

Decibel Therapeutics, Inc. Files Form 15

New major risk - Revenue and earnings growth

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index

Decibel Therapeutics, Inc. Announces Board Changes

Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) entered into a definitive agreement to acquire remaining unknown majority stake in Decibel Therapeutics, Inc. (NasdaqGS:DBTX) from a group of shareholders for approximately $100 million.

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Price target increased by 13% to US$15.33

Consensus EPS estimates upgraded to US$1.89 loss

Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to Initiate Clinical Development of Lead Gene Therapy Candidate Db-OTO

Price target decreased by 7.4% to US$12.60

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

PDecibel Therapeutics, Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

Consensus revenue estimates fall by 25%

High number of new directors

Decibel Therapeutics, Inc. Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate Db-Oto

High number of new directors

Price target decreased to US$14.60

Decibel Therapeutics, Inc. Receives Fda Clearance of Ind Application for Db-Oto, A Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO

Decibel Therapeutics, Inc. Announces Executive Changes

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Price target decreased to US$15.40

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

Price target decreased to US$14.75

Consensus forecasts updated

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$17.00

Less than half of directors are independent

Price target decreased to US$21.33

Decibel Therapeutics Announces the Presentation of Preclinical Data on Lead Gene Therapy Product Candidate, DB-OTO and Preclinical Data Highlighting the Identification of Proprietary

Less than half of directors are independent

Chief People notifies of intention to sell stock

President recently bought US$76k worth of stock

Vice President of Finance & Principal Accounting Officer Ronald Vigliotta has left the company

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$2.08m

Investor sentiment deteriorated over the past week

Decibel Therapeutics: Gene Therapies For Hearing Loss

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from Russell Microcap Growth Index

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Decibel Therapeutics, Inc. Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations

Decibel Therapeutics, Inc. has completed an IPO in the amount of $127.116 million.

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Decibel Therapeutics, Inc. Samenvatting

0.0x

-2.0x

Inkomsten en omzet